Loading…
ABVX
Abivax S.A.
NASDAQ· Healthcare· Biotechnology
$113.35-0.83%
Key metrics
- Market cap
- $9.89B
- P/E
- —
- Forward P/E
- —
- P/B
- 18.0x
- Dividend yield
- —
- EPS
- -$5.38
- ROE
- -157.07%
- Profit margin
- 0.00%
- Revenue growth
- +35.20%
- Beta
- -0.23
- 52-week high
- $148.83
- 52-week low
- $69.81
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
- 80
- Paris, France
Company description provided by Yahoo Finance.